Ongoing Research While tirzepatide has proven effective at lowering blood sugar and promoting weight loss, uncertainties remain regarding its long-term safety and benefits: Clinical trials like SURMOUNT-1 are evaluating tirzepatides efficacy and side effects in overweight or obese adults without diabetes
Evidence-Based Longevity : We utilize FDA-approved GLP-1 agonist medications, which are clinically studied for long-term use
Research Observation: A 2025 review specifically examined its effect on GLP-1 and insulin secretion, identifying the bacterium's capacity to stimulate GLP-1 production as a key mechanism
Keep the pen away from the refrigerators cooling element
Lillys dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) agonist tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity and sleep apnea, has also shown promise for people with MASH and Stage F2 to F3 fibrosis
Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation
